当CFTR功能在药理上得到改善时,氧化应激和炎症可以有多有效地逆转?
Valeria Rachela Villella1, Alice Castaldo2,3, Filippo Scialò1,4
1CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
Antioxidants (Basel, Switzerland)
|April 14, 2025
概括
三重疗法在囊性纤维化中部分恢复CFTR功能,减少感染和炎症. 然而,持续的氧化应激需要新的抗氧化和抗炎疗法来治疗晚期肺部疾病.
科学领域:
- 肺部医学 肺部医学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 囊性纤维化 (CF) 治疗的进展包括像elexacaftor-tezacaftor-ivacaftor (ETI) 这样的调节器疗法.
- 在至少有一个F508del突变的个体中,ETI部分恢复CFTR功能.
- 虽然ETI减少了病原体负荷和炎症,但残留的氧化应激和炎症仍然存在.
研究的目的:
- 为了研究持续的氧化应激和炎症在囊性纤维化患者尽管调节器治疗.
- 探索多omics技术的潜力,以了解这些持久的途径.
- 为了确定恢复呼吸道健康的新型治疗点.
主要方法:
- 对基因表达,表观遗传修饰,蛋白质概况和代谢过程的分析.
- 利用接受ETI治疗的患者的气道衍生样本.
- 采用新兴的多领域技术.
主要成果:
- 在ETI治疗中,CFTR功能部分恢复到正常水平的50%左右.
- 观察到唾液病原体含量显著减少,增强微生物群多样性,降低炎症标志物.
- 持续的残留呼吸道感染,氧化应激和炎症仍然存在,与非CF支气管炎症相比.
结论:
- 通过ETI疗法恢复部分CFTR功能提供了临床益处,但不能完全解决氧化应激和炎症.
- 创新的抗氧化和抗炎策略至关重要,特别是在晚期囊性纤维化肺病中.
- 多omics方法有望阐明持久性病理的机制,并确定新的治疗点.
更多相关视频
相关概念视频
Cystic Fibrosis: Management
105
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
105
Cystic Fibrosis: Pathogenesis
145
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
145
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
133
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
133
Drugs Used in Lower Respiratory Disorders: Overview
260
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
260
Acute Respiratory Failure-V
110
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
110


